FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2022243516> ?p ?o ?g. }

• W2022243516 endingPage "601" @default.
• W2022243516 startingPage "595" @default.
• W2022243516 abstract "New, better tolerated and faster treatments for depression are needed. Patients are understandably unhappy with having to wait 3 to 4 weeks for a response to an antidepressant, while experiencing side effects almost immediately. This frequently has an adverse effect on compliance and engagement with treatment.The primary objective was to assess the activity of pindolol on the onset of antidepressive response of milnacipran. The secondary objective was to assess the number of responders among the patients who received milnacipran and pindolol versus patients who received milnacipran and placebo. The tertiary objective was to evaluate the safety of milnacipran and pindolol versus milnacipran and placebo.Randomized, double-blind, placebo-controlled study over 42 days.Inner city London community mental health teams.80 patients were selected and gave written consent to treatment, 78 were randomized (39 in each group) and evaluated for safety (intention-to-treat, ITT, safety data set), 77 (ITT efficacy data set), and 64 (per protocol, PP, data set) were evaluated for efficacy. The mean age was 31.9 for the pindolol group and 32.3 for the placebo.All patients received milnacipran 50 mg twice a day plus either pindolol 2.5 mg (the 'pindolol group') or matching placebo (the 'placebo group') three times a day.The main efficacy variable was the Montgomery-Asberg depression rating scale (MADRS) score at days 0, 4, 7, 10, 14, 21, 28, 42 on PP data set in an observation carried (OC) approach. Secondary efficacy variables were clinical global impression (global improvement) and Hamilton depression rating scale (HDRS).Improvement in MADRS total score was greater in the pindolol group than in the placebo group from day 7 (p=0.03). Responder rates in the clinical global impression were 97.2% for the pindolol group and 60.6% for the placebo group. The treatment was well tolerated with the most common side effects being nausea (28.2%; 35.9%), vomiting (7.7%; 23.1%), hot flushes (15.4%; 5.1%) and sweating (12.8%; 12.8%).The milnacipran and pindolol combination is safe, well tolerated and efficacious in major depression, and represents a rational strategy for the possible acceleration or potentiation of antidepressant action." @default.
• W2022243516 created "2016-06-24" @default.
• W2022243516 creator A5011469305 @default.
• W2022243516 creator A5045136194 @default.
• W2022243516 creator A5066541863 @default.
• W2022243516 creator A5080055223 @default.
• W2022243516 date "2003-01-01" @default.
• W2022243516 modified "2023-09-27" @default.
• W2022243516 title "Milnacipran and pindolol: a randomized trial of reduction of antidepressant latency" @default.
• W2022243516 cites W1968874166 @default.
• W2022243516 cites W1987446423 @default.
• W2022243516 cites W1990228773 @default.
• W2022243516 cites W1992221341 @default.
• W2022243516 cites W1994702289 @default.
• W2022243516 cites W1997880525 @default.
• W2022243516 cites W1998088135 @default.
• W2022243516 cites W2004852769 @default.
• W2022243516 cites W2007046516 @default.
• W2022243516 cites W2007490806 @default.
• W2022243516 cites W2011952312 @default.
• W2022243516 cites W2012975250 @default.
• W2022243516 cites W2018085592 @default.
• W2022243516 cites W2027011765 @default.
• W2022243516 cites W2029830358 @default.
• W2022243516 cites W2037003575 @default.
• W2022243516 cites W2048283236 @default.
• W2022243516 cites W2054111879 @default.
• W2022243516 cites W2061378977 @default.
• W2022243516 cites W2072341886 @default.
• W2022243516 cites W2075623469 @default.
• W2022243516 cites W2076112136 @default.
• W2022243516 cites W2079669517 @default.
• W2022243516 cites W2081423757 @default.
• W2022243516 cites W2082152629 @default.
• W2022243516 cites W2106405415 @default.
• W2022243516 cites W2110634897 @default.
• W2022243516 cites W2128097815 @default.
• W2022243516 cites W2128427818 @default.
• W2022243516 cites W2131823335 @default.
• W2022243516 cites W2150215731 @default.
• W2022243516 cites W2150910901 @default.
• W2022243516 cites W2160325982 @default.
• W2022243516 cites W2321329826 @default.
• W2022243516 cites W2322350033 @default.
• W2022243516 cites W2402252666 @default.
• W2022243516 doi "https://doi.org/10.1002/hup.524" @default.
• W2022243516 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/14696018" @default.
• W2022243516 hasPublicationYear "2003" @default.
• W2022243516 type Work @default.
• W2022243516 sameAs 2022243516 @default.
• W2022243516 citedByCount "11" @default.
• W2022243516 crossrefType "journal-article" @default.
• W2022243516 hasAuthorship W2022243516A5011469305 @default.
• W2022243516 hasAuthorship W2022243516A5045136194 @default.
• W2022243516 hasAuthorship W2022243516A5066541863 @default.
• W2022243516 hasAuthorship W2022243516A5080055223 @default.
• W2022243516 hasConcept C118552586 @default.
• W2022243516 hasConcept C126322002 @default.
• W2022243516 hasConcept C138496976 @default.
• W2022243516 hasConcept C142724271 @default.
• W2022243516 hasConcept C15744967 @default.
• W2022243516 hasConcept C168563851 @default.
• W2022243516 hasConcept C197934379 @default.
• W2022243516 hasConcept C204787440 @default.
• W2022243516 hasConcept C27081682 @default.
• W2022243516 hasConcept C2776000289 @default.
• W2022243516 hasConcept C2778151854 @default.
• W2022243516 hasConcept C2778499207 @default.
• W2022243516 hasConcept C2779177272 @default.
• W2022243516 hasConcept C2780051608 @default.
• W2022243516 hasConcept C2780199185 @default.
• W2022243516 hasConcept C2780733359 @default.
• W2022243516 hasConcept C2781161787 @default.
• W2022243516 hasConcept C42219234 @default.
• W2022243516 hasConcept C71924100 @default.
• W2022243516 hasConcept C83849319 @default.
• W2022243516 hasConceptScore W2022243516C118552586 @default.
• W2022243516 hasConceptScore W2022243516C126322002 @default.
• W2022243516 hasConceptScore W2022243516C138496976 @default.
• W2022243516 hasConceptScore W2022243516C142724271 @default.
• W2022243516 hasConceptScore W2022243516C15744967 @default.
• W2022243516 hasConceptScore W2022243516C168563851 @default.
• W2022243516 hasConceptScore W2022243516C197934379 @default.
• W2022243516 hasConceptScore W2022243516C204787440 @default.
• W2022243516 hasConceptScore W2022243516C27081682 @default.
• W2022243516 hasConceptScore W2022243516C2776000289 @default.
• W2022243516 hasConceptScore W2022243516C2778151854 @default.
• W2022243516 hasConceptScore W2022243516C2778499207 @default.
• W2022243516 hasConceptScore W2022243516C2779177272 @default.
• W2022243516 hasConceptScore W2022243516C2780051608 @default.
• W2022243516 hasConceptScore W2022243516C2780199185 @default.
• W2022243516 hasConceptScore W2022243516C2780733359 @default.
• W2022243516 hasConceptScore W2022243516C2781161787 @default.
• W2022243516 hasConceptScore W2022243516C42219234 @default.
• W2022243516 hasConceptScore W2022243516C71924100 @default.
• W2022243516 hasConceptScore W2022243516C83849319 @default.
• W2022243516 hasIssue "8" @default.
• W2022243516 hasLocation W20222435161 @default.

• next